This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Viral Infections  • Adverse Effects  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

Arch Intern Med. 2001;161:1677-1678.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Acute fulminant hepatitis has been attributed to rare idiosyncratic drug reactions associated with several common medications. We report here a case of fulminant hepatitis initially ascribed to the use of terbinafine for onychomycosis that may instead have been caused by the use of a relatively new proton-pump inhibitor, rabeprazole sodium, for gastroesophageal reflux disease.

Report of a Case

A previously healthy 46-year-old man presented to an outside hospital with acute onset jaundice following 2 weeks of "flulike" symptoms. His initial total bilirubin level was 1.2 mg/dL (21 µmol/L) and transaminase level was greater than 3000 U/L, but serologic findings were negative for hepatitis. Findings from abdominal ultrasound including the biliary tree was unremarkable. Over the ensuing week he became encephalopathic and his creatinine level rose from initially normal values to 5.2 mg/dL (460 µmol/L), which prompted the transfer to our institution for emergency liver transplantation and suspected hepatorenal syndrome. At this time terbinafine use . . . [Full Text of this Article]

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Acute Fulminant Hepatitis After Treatment With Rabeprazole and Terbinafine: Is Rabeprazole the Culprit?
Andrade et al.
Arch Intern Med 2002;162:360-361.
FULL TEXT